title: Serum HE4 as a diagnostic and prognostic marker for lung cancer.
abstract: We evaluated the diagnostic and prognostic efficacy of human epididymis protein 4 (HE4) for lung cancer patients by using our novel enzyme-linked immunosorbent assay (ELISA) system. We measured serum HE4 levels of cancer patients including 49 lung cancer and 18 ovarian cancer patients. Furthermore, we evaluated the relationship between serum HE4 levels and overall survival after chemotherapy of 24 lung cancer patients. Serum HE4 levels were significantly higher for non-small, small cell lung cancer and ovarian cancer patients than for healthy controls. The area under the receiver operating characteristic curve (AUC) was calculated for differentiation of lung cancer patients and healthy controls. AUC for serum HE4 was 0.988 for differentiating lung cancer patients from healthy controls, with a cutoff value of 6.56 ng/ml (sensitivity = 89.8%, specificity = 100%). Serum HE4 levels were elevated in 36/40 (90.0%) non-small cell lung cancer patients, 8/9 (88.9%) small cell lung cancer patients and 8/18 (44.4%) ovarian cancer patients. High levels of serum HE4 (>15 ng/ml) after chemotherapy were significantly correlated with worse overall survival after the treatment. These findings suggest that serum HE4 is a potential diagnostic and prognostic marker for lung cancer patients.
authors.affiliation: Laboratory for Immune Signal, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.
authors.forename: Kota
authors.initials: K
authors.lastname: Iwahori
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Suzuki
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Kishi
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Fujii
authors.forename: Rie
authors.initials: R
authors.lastname: Uehara
authors.forename: Norio
authors.initials: N
authors.lastname: Okamoto
authors.forename: Masashi
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Tomonori
authors.initials: T
authors.lastname: Hirashima
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kawase
authors.forename: Tetsuji
authors.initials: T
authors.lastname: Naka
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis; D011379:Prognosis; D011506:Proteins / Q000378:metabolism*; D012372:ROC Curve; D012016:Reference Values; D055752:Small Cell Lung Carcinoma / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D016896:Treatment Outcome; D000081102:WAP Four-Disulfide Core Domain Protein 2; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D011506:Proteins; D000081102:WAP Four-Disulfide Core Domain Protein 2; C569698:WFDC2 protein, human